Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -4.74 is 100% above its 5-year average of -1006.80, near the high end of its 5-year range (-2523.77–-4.32).
6.69% above its 12-month average of -5.08.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.83.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 28 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T12:05:39.828Z. Historical observations retain their original dates. Historical series through 2018-05-11.
EARNINGS PER SHARE (EPS)
-4.74
EARNINGS PER SHARE (EPS) AVG TTM
-5.08
EARNINGS PER SHARE (EPS) AVG 3Y
-296.60
EARNINGS PER SHARE (EPS) AVG 5Y
-1006.80
EARNINGS PER SHARE (EPS) AVG 10Y
-759.92
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+6.69%
CURRENT VS 3Y AVG
+98.40%
CURRENT VS 5Y AVG
+99.53%
CURRENT VS 10Y AVG
+99.38%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Avalo Therapeutics, Inc.
Market Cap
$767.46M
Earnings Per Share (EPS)
-4.74
TTM Avg
-5.08
3Y Avg
-296.60
5Y Avg
-1006.80
Market Cap
$774.32M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.23
3Y Avg
-1.23
5Y Avg
-1.23
Market Cap
$775.72M
Earnings Per Share (EPS)
-1.18
TTM Avg
-1.05
3Y Avg
-1.11
5Y Avg
-0.92
Market Cap
$776.24M
Earnings Per Share (EPS)
-0.10
TTM Avg
-0.20
3Y Avg
-0.27
5Y Avg
-0.29
Market Cap
$780.95M
Earnings Per Share (EPS)
-1.68
TTM Avg
0.05
3Y Avg
-1.18
5Y Avg
-0.72
Market Cap
$749.55M
Earnings Per Share (EPS)
-1.41
TTM Avg
-1.23
3Y Avg
-0.97
5Y Avg
-1.16
Market Cap
$786.48M
Earnings Per Share (EPS)
-0.62
TTM Avg
-0.28
3Y Avg
-0.16
5Y Avg
-0.10
Market Cap
$734.10M
Earnings Per Share (EPS)
-2.76
TTM Avg
-3.16
3Y Avg
-2.11
5Y Avg
-1.54
Market Cap
$719.64M
Earnings Per Share (EPS)
-1.55
TTM Avg
-1.25
3Y Avg
-1.99
5Y Avg
-2.90
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | $767.46M | -4.74 | -5.08 | -296.60 | -1006.80 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | N/A | -1.23 | -1.23 | -1.23 |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | -1.18 | -1.05 | -1.11 | -0.92 |
| Geron Corporation (GERN)vs › | $776.24M | -0.10 | -0.20 | -0.27 | -0.29 |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | -1.68 | 0.05 | -1.18 | -0.72 |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -1.41 | -1.23 | -0.97 | -1.16 |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -0.62 | -0.28 | -0.16 | -0.10 |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | -2.76 | -3.16 | -2.11 | -1.54 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | -1.55 | -1.25 | -1.99 | -2.90 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 1.24 | 2.06 | 1.25 | 1.30 |
Trailing EPS (TTM)
$-4.74
Forward EPS (Est.)
$-2.92
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -5.84 |
| 2024-12-31 | -4.32 |
| 2023-12-31 | -113.58 |
| 2022-12-31 | -1062.65 |
| 2021-12-31 | -2330.66 |
| 2020-12-31 | -2523.77 |
| 2019-12-31 | -819.74 |
| 2018-12-31 | -3317.28 |
| 2017-12-31 | 1856.88 |
| 2016-12-31 | -21.93 |
| 2015-12-31 | -16.21 |
| 2014-12-31 | -41.61 |
| 2013-12-31 | -43.12 |
| 2012-12-31 | -199.77 |
